Ina-Respond
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
90.9%
+4.4% vs industry average
9%
1 trials in Phase 3/4
30%
3 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Dendritic Cell Vaccine to Prevent COVID-19
Role: lead
International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Role: collaborator
Observational Research on Infectious Disease Outbreaks and Difficult Cases of Unidentified Etiology in Indonesia
Role: lead
Tuberculosis Research of INA-RESPOND On Drug Resistance
Role: lead
HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia
Role: lead
Evaluation of GeneXpert HIV-1 as The Gold Standard Test for HIV-1 Viral Load Count
Role: lead
The Etiology of Acute Febrile Illness Requiring Hospitalization
Role: lead
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
Role: lead
Validation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum
Role: lead
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients
Role: lead
Integration of Mental Health in HIV Clinic to Increase the Success of ARV Treatment in PLWHA in Hospitals
Role: lead
All 11 trials loaded